Research advances in sorafenib-induced apoptotic signaling pathways in liver cancer cells / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 816-820, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-778622
ABSTRACT
Currently, sorafenib is the multi-target inhibitor for the treatment of advanced primary liver cancer, and can effectively prolong the progression-free survival and overall survival in patients with advanced primary liver cancer. The application of sorafenib in the targeted therapy for liver cancer has become a hot topic. Major targets or signaling pathways include Raf/Mek/Erk, Jak/Stat, PI3K/Akt/mTOR, VEGFR and PDGFR, STAT, microRNA, Wnt/β-catenin, autolysosome, and tumor-related proteins, and sorafenib can regulate the proliferation, differentiation, metastasis, and apoptosis of liver cancer cells through these targets. This article reviews the current research on the action of sorafenib on these targets or signaling pathways to provide useful references for further clinical research on sorafenib.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS